Vimarsana
Biggest News Aggregation in the World

Broad Potential News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Broad Potential. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Broad Potential Today - Breaking & Trending Today

Light Levels Can Impact Cognitive Performance and Sleep Quality - Vimarsana News

Light Levels Can Impact Cognitive Performance and Sleep Quality

New research suggests that exposure to higher light levels can enhance wakefulness and cognitive performance by influencing the hypothalamus.

Artax Announces First Patient Dosed in Phase 2a Psoriasis Trial Evaluating AX-158 - Vimarsana News

Artax Announces First Patient Dosed in Phase 2a Psoriasis Trial Evaluating AX-158

/PRNewswire/ -- Artax Biopharma, Inc., a clinical-stage biotechnology company focused on transforming the treatment of autoimmune diseases, today announces...

Gilead Bets $405M on MiroBio's Checkpoint Agonists for Autoimmune Disease - Vimarsana News

Gilead Bets $405M on MiroBio's Checkpoint Agonists for Autoimmune Disease

Gilead snapped up U.K.-based MiroBio in a $405 million deal that will bring its checkpoint agonists and discovery platform under Gilead's umbrella.

Antengene Announces Commercial - GuruFocus.com - Vimarsana News

Antengene Announces Commercial - GuruFocus.com

GuruFocus Article or News written by PRNewswire and the topic is about:

Antengene Announces Commercial Availability of XPOVIO® (Selinexor), for the Treatment of Relapsed/Refractory Multiple Myeloma, Prescribed for the First Time Across Mainland China - Vimarsana News

Antengene Announces Commercial Availability of XPOVIO® (Selinexor), for the Treatment of Relapsed/Refractory Multiple Myeloma, Prescribed for the First Time Across Mainland China

/PRNewswire/ -- Antengene Corporation Limited ("Antengene" SEHK: 6996.HK), a leading innovative, commercial-stage global biopharmaceutical company dedicated to...